MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH COVID-19 (systematic review)

Abstract

The prevalence of multisystem inflammatory syndrome in children (MIS-C) has increased since the beginning of the 2019 coronavirus disease pandemic (COVID-19) [1]. The aim of this study was to describe the clinical manifestations and outcomes of MIS-C associated with COVID-19[2,3]. This systematic review and meta-analysis was conducted across all available literature until October 10, 2022. To evaluate the combined assessments, data on gender, ethnicity, clinical manifestations, the need for artificial lung ventilation or hospitalization in the intensive care unit (ICU), imaging, cardiac complications and laboratory results of COVID-19 were extracted [1, 4-7]. It was based on 3 meta-analyses on the topic of multisystem inflammatory syndrome in children with COVID-19, where a total of 98 articles (2,275 patients) with demographic data, clinical treatment and outcomes of patients diagnosed with MIS-C. were selected.

Начало формы

Конец формы

The average age of children with MIS-C, 56.8% of whom were male, was nine years. Fever (100%), gastrointestinal tract (82%) and abdominal pain (68%) were the decisive symptoms for the diagnosis of MIS-C. Shock and/or hypotension were frequent in patients with MIS-C. Cardiac symptoms (66%) prevailed over respiratory (39%) and neurological (28%) symptoms. The treatment of MIS-C corresponded to the general recommendations for the treatment of children with septic shock and Kawasaki disease and proved to be effective[8]. The results of this meta-analysis based on current evidence showed that common clinical manifestations of MIS-C associated with COVID-19 include a combination of fever and skin-mucosal lesions similar to atypical Kawasaki disease and multiple organ dysfunction[9,10]. Due to the relatively higher morbidity and mortality, it is very important to diagnose this condition in a timely manner[11].